Pfizer has again suspended production at a long-troubled sterile injectables plant in India that the FDA has twice before cited.
China is helping Indian drugmakers navigate its regulations and has worked out "measures on promoting China-India pharmaceutical trade cooperation."
South Korean investment firm SK Holdings has made a move on the U.S. with a deal to buy CDMO AMPAC.
Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.
South Korean regulators have ruled on a case of alleged accounting violations at Samsung BioLogics and sent their findings to prosecutors.
With Johnson & Johnson's diabetes drug Invokana going up against two longtime rivals in China, the company is ramping things up.
The FDA issued a warning letter after an inspection of the China plant where Zhuhai United Laboratories makes sterile drugs.
Nasdaq-listed Sinovac accused OrbiMed, 1Globe Capital and a buyer consortium led by Sinobioway of conspiring a hostile takeover.
Zhejiang Huahai Pharmaceutical informed the EMA that it had identified a chemical that might lead to cancer in its valsartan provided to the European market.
A film based on the true story of a leukemia patient smuggling Indian generics has led Beijing to reiterate its intention to cut cancer drug prices.